National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dabrafenib (Tafinlar® ) is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.

 Rapid Review

Commenced Completed Outcome
11/09/2013 02/10/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 03/12/2013  24/06/2014 Reimbursement Recommended

 The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib. 

 Summary Report for dabrafenib